Department of Pediatrics, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.
Division of Pediatric Neurology, Chang Gung Children's Hospital and Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Pediatr Neonatol. 2021 Mar;62(2):181-186. doi: 10.1016/j.pedneo.2020.08.014. Epub 2020 Dec 3.
Craniopharyngiomas are benign tumors of embryologic origin located in the sellar region. Patients have both neurological and endocrinological symptoms. Symptoms may be subtle in the early clinical course, which leads to delayed diagnosis. This study evaluated the clinical and endocrinological manifestations of childhood-onset craniopharyngioma.
We retrospectively reviewed medical records of 45 children diagnosed as having craniopharyngioma between 1995 and 2019. We collected data on clinical symptoms and signs, height, weight, biochemical and hormone data, images, operation records, and pathology reports. A three-graded classification system was applied to define the degree of hypothalamic damage (HD). We analyzed clinical and endocrinological manifestations among patients with and without obesity, with short and normal stature, and with differing degrees of HD.
Clinical endocrinologic manifestations included adrenocortical insufficiency (42%), central hypothyroidism (37%), short stature (31%), obesity (20%), weight < third percentile (19%), and polyuria or polydipsia (11%). The distribution of height and body mass index (BMI) revealed that a relatively large proportion of patients had short stature and obesity compared to the general population. Patients with grade 2 HD were significantly taller (height median SDS -0.07 vs. -2.05, P = 0.032), and had higher BMI (BMI median standard deviation scores [SDS] 1.14 vs. -0.54, P = 0.039) and shorter time to diagnosis (0.27 vs. 8.29 months, P = 0.007) than were those in the grade 0-1 HD. Delayed diagnosis was associated with short stature (6/7 vs. 4/26, P = 0.001) and no initial neurological symptoms (4/7 vs. 2/28, P = 0.009).
Growth patterns may change variously depend on the tumor location and the severity of hypothalamic damage. Therefore, monitoring possible neurological symptoms and evaluating the growth patterns of patients during regular outpatient clinical visits are paramount.
颅咽管瘤是起源于胚胎的良性肿瘤,位于蝶鞍区。患者有神经和内分泌症状。在早期临床过程中,症状可能不明显,导致诊断延迟。本研究评估了儿童颅咽管瘤的临床和内分泌表现。
我们回顾性分析了 1995 年至 2019 年间诊断为颅咽管瘤的 45 名儿童的病历。我们收集了临床表现和体征、身高、体重、生化和激素数据、图像、手术记录和病理报告。应用三级分类系统定义下丘脑损伤(HD)程度。我们分析了肥胖症、身材矮小、不同程度 HD 患者的临床和内分泌表现。
临床内分泌表现包括肾上腺皮质功能不全(42%)、中枢性甲状腺功能减退(37%)、身材矮小(31%)、肥胖症(20%)、体重<第 3 百分位数(19%)和多尿或多饮(11%)。身高和体重指数(BMI)的分布显示,与一般人群相比,相当大比例的患者身材矮小和肥胖。HD 分级 2 组患者明显更高(身高中位数 SDS-0.07 比-2.05,P=0.032),BMI 更高(BMI 中位数标准差评分[SDS]1.14 比-0.54,P=0.039),诊断时间更短(0.27 比 8.29 个月,P=0.007),HD 分级 0-1 组。诊断延迟与身材矮小(6/7 比 4/26,P=0.001)和无初始神经症状(4/7 比 2/28,P=0.009)相关。
肿瘤位置和下丘脑损伤严重程度的不同,生长模式可能会发生变化。因此,在常规门诊就诊期间监测可能的神经症状并评估患者的生长模式至关重要。